Normal blood sugar control target: fasting blood glucose 130 mg/dL, postprandial blood glucose 160-180 mg/dL, glycosylated hemoglobin below 7% (the control target will vary slightly according to different ages and clinical conditions). When the glycosylated hemoglobin is 8.5%: the average blood sugar is above 200 mg/dL, which is equivalent to fasting blood sugar close to 200 mg/dL, postprandial blood sugar 250-260 mg/dL, and such a value is far from the recommended target. Dr. Li Hongyuan pointed out that those who do not meet the above-mentioned health insurance payment standards must use incretin at their own expense, which will cost an average of 3,000 to 4,000 yuan per month, not including outpatient registration, diagnosis and treatment, care and other related expenses, which accumulate over a long period of time. The amount is considerable. Therefore, under the current health insurance payment conditions, many people with diabetes are unable to use incretin therapy as soon as possible due to financial constraints, even if their blood sugar is not well controlled, further increasing the risk of cardio-renal comorbidities.
This result is not only a big blow to the control of diabetes Photo Restoration Service patients, but also does not help to reduce the overall health care financial expenditure in the long run. Payback in 3 years! Diabetes Care Foundation: I hope to create a win-win situation by repairing the payment conditions of incretin health insurance Regarding this situation, Dr. Li Hongyuan emphasized that although he agrees that in order to maintain the long-term operation of Taiwan's medical system, health insurance financial considerations are necessary. However, in terms of long-term goals, the current health insurance payment standards for incretin are not only counterintuitive in clinical practice, but also inconsistent with the current international situation. Dr. Li Hongyuan further shared that, looking at the drug payment standards of neighboring countries in Asia, there are no similar restrictions on the use of incretin in Japan, South Korea, and mainland China; there is no country in the world that requires glycosylation of hemoglobin like Taiwan. More than 8.5%, and it can be opened for up to half a year. At the same time.
Dr. Li Hongyuan said that according to the calculation data of the Diabetes Society and medical economics experts, if the incretin payment standard can be revised down from 8.5% of glycosylated hemoglobin to 7.5%, although the cost of medicines will increase in the short term, but in the first From three years onwards, due to the reduction of major cardiovascular and renal complications, the health insurance expenditure can be reduced by about 23 million points, which is equivalent to the sum of the increased drug expenditure in the previous two years; and about 68 million and 68 million yuan can be saved in the fourth and fifth years respectively. At 124 million points, in the long run, the expected reduction in health care spending will be considerable.